Purdue Pharma introduces new packaging for Colace and Senokot
Purdue Pharma's Colace product line and Senokot tablets will now come with new packaging. Read More »
Plaintiff lawyer ads may scare some Americans from taking their prescriptions, finds new survey
Do television ads by plaintiffs' lawyer firms hawking lawsuits over prescription drugs cause patients to cease taking their prescribed prescriptions? Read More »
Alkermes begins Phase 3b trial for major depressive disorder drug
Commencing a Phase 3b trial of daily oral medication ALKS 5461, Alkermes PLC will assess the treatment’s feasibility and safety for major depressive disorder patients with insufficient prior results obtained from other drugs. Read More »
Health Affairs Blog reviews issue of surprise medical bills
The Health Affairs Blog, a vehicle for commentary on health policy and issues affecting the health care industry, recently release an article on surprise medical bills. Read More »
MD Logistics to expand Indiana operations, creating 50 new jobs
MD Logistics, a third-party logistics company that works with pharmaceutical companies, will expand its Indiana operations, creating 50 new jobs in the process. Read More »
Merck pauses enrollment in Keytruda's Phase III studies
Merck has paused enrollment in two Keytruda clinical trials. Read More »
Study shows gifts, relationships with drug company representatives, influence physicians
A new study published in the Journal of the American Medical Association finds that doctors are influenced by gifts and their relationships with drug company representatives. Read More »
Drug Channels comments on CMS's report on Medicare Part D and DIR
Drug Channels, a website providing expert insights on pharmaceutical economics and the drug distribution system, recently commented on a new report from the Centers for Medicare & Medicaid Services, titled “Medicare Part D – Direct and Indirect Remuneration.” Read More »
Sandoz introduces authorized generic version of Pataday
Sandoz has introduced the authorized generic version of Alcon Research Ltd.'s Pataday, an olopatadine hydrochloride ophthalmic solution. Read More »
Omnicell, CompleteRX partner to support Massachusetts pharmacy services
Omnicell Inc. announced an agreement with CompleteRX to develop a medication distribution model for the Commonwealth of Massachusetts State Office of Pharmacy Services. Read More »
Teva launches generic version of Zetia in U.S.
Global generic pharmaceutical giant Teva recently released its generic version of Zetia (ezetimibe) in 10mg tablets to address total and low-density lipoprotein (LDL) blood cholesterol levels for U.S. patients, company officials announced from Jerusalem headquarters. Read More »
FDA asks Endo to suspend sales of injectable opioid
After documenting recent product abuse, the U.S. Food and Drug Administration asked Endo Pharmaceuticals to voluntarily remove its reformulated Opana ER (oxymorphone hydrochloride) opioid medication from circulation, stating that risks may now outnumber benefits. Read More »
FDA authorizes Aristada in diverse doses to combat schizophrenia
Alkermes PLC’s Aristada (aripiprazole lauroxil) injectable medication has won approval from the U.S. Food and Drug Administration as an extended-release injectable suspension to treat schizophrenia. Read More »
Sanofi Pasteur announces U.S. availability of Quadracel vaccine
Sanofi Pasteur's Quadracel vaccine has been approved by the U.S. Food and Drug Administration to protect children between the ages of 4 and 6 against diphtheria, tetanus, pertussis and poliomyelitis. Read More »
Astellas, Seattle Genetics reveal new urothelial cancer treatment data
Astellas, a global pharmaceutical corporation with U.S. headquarters in Northbrook, Illinois, and biotechnology company Seattle Genetics recently publicized findings on their enfortumab vedotin (ASG-22ME) treatment for a type of cancer commonly manifesting in the bladder. Read More »
ReachBio Research Labs launches cellPrism to deliver customized in-vitro assays
ReachBio Research Labs recently announced that it launched cellPrism, a drug development platform designed to deliver a spectrum of customized in-vitro assays to biotechnology and pharmaceutical companies. Read More »
OneOme's Rightmed test can pinpoint best medications for patients
OneOme, the company behind the OneOme RightMed pharmacogenomics test, recently delivered a statement about how DNA has the power to minimize medication trial and error and help people with heart conditions improve their cardiovascular treatments. Read More »
Enanta and AbbVie receive green light to study hepatitis C drug
Enanta Pharmaceuticals Inc.'s New Drug Application (NDA) for its pan-genotypic regimen of glecaprevir/pibrentasvir (G/P), developed in conjunction with AbbVie, has been accepted by the U.S Food and Drug Administration. Read More »
Study shows promise for antiandrogens in prostate cancer treatment
The American Pharmacists Association (APA) recently announced that new research shows adding 24 months of antiandrogen therapy with daily bicalutamide to salvage radiation therapy led to an increase in survival rates and for patients with recurrent prostate cancer. Read More »
Daiichi Sankyo, Inspirion Delivery Sciences to market RoxyBond tablets in U.S.
Daiichi Sankyo Inc. will take the helm on handling U.S. commercialization of the FDA-approved RoxyBond (oxycodone hydrochloride) oral-use medication manufactured by Inspirion Delivery Sciences LLC, the companies announced recently from their respective New Jersey hubs. Read More »
Alerts Sign-up